This past week Perrigo and its partner Allergan announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store-brand equivalent to Mucinex 1200mg extended-release tablets to retail and wholesale customers. First shipments of this new private brand product have been initiated and represents a first-to-market accomplishment for Perrigo and Allergan.
“This product approval and launch demonstrates the power of matching Perrigo’s OTC platform with Allergan’s world-class generics R&D capabilities,” stated Joseph Papa, Perrigo chairman and CEO. “Our teams together worked to bring this important product to our consumers and customers around the world. The Mucinex family of products is an important offering to our customers and we look forward to launching the remaining products throughout 2016.”
Mucinex 1200mg extended-release tablets (guaifenesin 1200mg extended-release tablets), indicated to relieve chest congestion and to break up mucus, making coughs more productive, produced sales of approximately $71 million through food, drug and mass merchants during that last twelve months, the companies reported.